PSA Test Explained: Normal Levels, Interpretation & Guidelines

What is PSA? (Prostate‑Specific Antigen)

PSA (prostate‑specific antigen) is a protein produced exclusively by the epithelial cells of the prostate gland. Its normal function is to liquefy semen after ejaculation, allowing sperm to swim freely.

PSA is a serine protease (kallikrein‑3, KLK3) that breaks down the gel‑forming proteins in semen (semenogelin I and II). Without PSA, semen would remain clotted, impairing fertility.

In healthy men, very little PSA enters the bloodstream. When the prostate is disrupted – by cancer, BPH, prostatitis, or trauma – PSA leaks into the blood, where it can be measured.

What is a PSA test?

The PSA test is a simple blood test that measures the amount of PSA in the bloodstream. It is used for:

• Screening: Detecting possible prostate cancer in asymptomatic men.
• Diagnosis: Evaluating men with urinary symptoms or abnormal DRE.
• Monitoring: Tracking disease progression or recurrence after treatment.

How it works: A blood sample is drawn from a vein in the arm. The lab measures total PSA (free + bound). Results are typically available within 1‑3 days.

Preparation: No fasting required. However, ejaculation, DRE, prostate biopsy, or urinary tract infections can temporarily elevate PSA. Patients should avoid ejaculation for 48 hours before testing.

Normal PSA levels by age – complete chart

"Normal" PSA levels vary by age because the prostate naturally grows over time. There is no universal cutoff – age‑specific ranges are more accurate.

Age Range	Normal PSA Range (ng/mL)	Action Threshold (ng/mL)	Clinical Note
40‑49 years	0.0‑2.5	>2.5	Screening controversial; discuss with doctor
50‑59 years	0.0‑3.5	>3.5	Screening recommended after shared decision‑making
60‑69 years	0.0‑4.5	>4.5	Higher threshold due to BPH
70‑79 years	0.0‑6.5	>6.5	Screening benefit declines after age 70
80+ years	0.0‑8.0	>8.0	Screening not recommended unless life expectancy >10 years

Important: These are general guidelines. Individual factors (race, prostate size, medications) affect normal ranges. African‑descent men may have higher normal PSA levels.

What causes elevated PSA? (Cancer, BPH, prostatitis, and more)

Elevated PSA does NOT automatically mean cancer. Common causes include:

• Prostate cancer (25‑35% of elevated PSA): Cancer cells disrupt the normal prostate architecture, releasing more PSA into blood.
• Benign Prostatic Hyperplasia (BPH – 40‑50%): Enlargement stretches prostate epithelial cells, increasing PSA leakage. BPH typically causes mild elevation (4‑10 ng/mL).
• Prostatitis (10‑15%): Inflammation causes PSA to rise dramatically, sometimes to >20 ng/mL. PSA usually returns to normal after treatment.
• Recent ejaculation (within 48 hours): Can raise PSA by 0.5‑1.0 ng/mL.
• Digital rectal exam (DRE): Minimal effect (<0.5 ng/mL).
• Urinary tract infection (UTI) or catheterisation: Inflammation raises PSA.
• Prostate biopsy or surgery (recent): Causes massive PSA elevation (resolves over weeks).
• Medications: 5‑alpha reductase inhibitors (finasteride, dutasteride) lower PSA by ~50%.

PSA screening guidelines (AUA, USPSTF, NCCN)

Guidelines have evolved significantly over the past decade. Current recommendations (2025‑2026) emphasise shared decision‑making:

American Urological Association (AUA) 2023 Guidelines:

• Ages 40‑54: No routine screening for average‑risk men. Offer screening to high‑risk men (African descent, strong family history).
• Ages 55‑69: Shared decision‑making – discuss benefits (reducing cancer death) and harms (overdiagnosis, overtreatment). Screen every 2‑4 years if PSA <1 ng/mL.
• Ages 70+ or life expectancy <10 years: No routine screening.

USPSTF (2023):

• Grade C for men aged 55‑69: Selective screening based on patient preference.
• Grade D for men 70+: Recommend against screening.

NCCN (2025):

• Baseline PSA at age 45 for all men.
• Annual or biennial screening based on PSA level and risk factors.

Bottom line: Discuss PSA screening with your doctor. It is not a "one‑size‑fits‑all" decision.

How to interpret PSA results – free PSA, density, velocity

When total PSA is borderline (4‑10 ng/mL), additional tests help distinguish cancer from BPH:

Free PSA (% free PSA):

• PSA exists in blood as free (unbound) or bound to proteins.
• % Free PSA = (Free PSA / Total PSA) × 100
• >25%: Low cancer risk (suggest BPH).
• 10‑25%: Intermediate risk – biopsy considered.
• <10%: High cancer risk – biopsy recommended.

PSA Density (PSAD):

• PSA divided by prostate volume (mL, from ultrasound).
• PSAD >0.15 ng/mL/mL: Suggests cancer (higher than expected for prostate size).
• PSAD <0.10: Low cancer risk.

PSA Velocity:

• Rate of PSA change over time (ng/mL per year).
• Increase >0.75 ng/mL/year: Elevated cancer risk (especially if persistent).
• Requires at least 3 PSA measurements over 18 months.

PSA Doubling Time:

• Time for PSA to double. Used for monitoring recurrence after treatment.
• Doubling time <3 months: Aggressive recurrence.
• Doubling time >12 months: Indolent disease.

When is a prostate biopsy recommended?

Biopsy is the only way to diagnose prostate cancer. Indications include:

• Elevated PSA with abnormal DRE: Biopsy regardless of PSA level.
• PSA >4 ng/mL (or age‑specific threshold) + risk factors.
• Persistently rising PSA velocity (>0.75 ng/mL/year).
• Abnormal MRI (PI‑RADS 4 or 5 lesions).
• % free PSA <10‑15% with total PSA 4‑10 ng/mL.

Biopsy is not automatically indicated for a single elevated PSA – repeat testing and additional markers (free PSA, PHI, 4Kscore, MRI) can reduce unnecessary biopsies.

Limitations of PSA testing – false positives and overdiagnosis

PSA testing has significant limitations that every man should understand:

• False positives (70‑80% of elevated PSAs are not cancer): Leading to unnecessary anxiety, repeat testing, and biopsies.
• False negatives (20% of prostate cancers have normal PSA): Especially aggressive high‑grade cancers may produce less PSA.
• Overdiagnosis: PSA detects many slow‑growing cancers that would never cause harm. Treatment of these (surgery, radiation) causes unnecessary side effects.
• Does not distinguish indolent from aggressive cancer: Additional tests (biopsy, MRI, genomic markers) are needed.

Despite these limitations, PSA screening has been shown to reduce prostate cancer mortality by 20‑30% in randomised trials. The key is intelligent use – not blanket screening or ignoring it entirely.

PSA after treatment – monitoring recurrence

PSA is the cornerstone of monitoring after prostate cancer treatment:

• After radical prostatectomy: PSA should be undetectable (<0.1 ng/mL). Two consecutive rises >0.2 ng/mL indicates biochemical recurrence (BCR).
• After radiation therapy: PSA declines slowly over 18‑36 months. The nadir (lowest PSA) should be <0.5 ng/mL. A rise >2 ng/mL above nadir is Phoenix criteria for recurrence.
• After hormone therapy (ADT): PSA should fall to undetectable levels. Rising PSA indicates castration‑resistant prostate cancer (CRPC).

Regular PSA monitoring after treatment (every 3‑12 months) allows early detection of recurrence and salvage therapy.

Interactive FAQ – PSA test explained

---

Disclaimer: This information is for educational purposes. PSA screening decisions should be made with your urologist based on your individual risk factors and preferences. Vivekananda Hospital offers comprehensive prostate cancer screening and management.